Teva slapped with €463M fine over accusations it stymied Copaxone competition in Europe

Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped.

The European Commission (EC) has fined Teva 462.6 million euros ($503 million) over allegations that the Israeli-American pharmaceutical giant “[abused] its dominant market position to delay competition” to Copaxone.